NASDAQ: XXII22nd Century Group Inc Stock
$0.85+0.04 (+4.94%)
Updated Apr 30, 2025
XXII Price
$0.85
Fair Value Price
N/A
Market Cap
$2.01M
52 Week Low
$0.70
52 Week High
$243.00
P/E
0x
P/B
0.5x
P/S
0.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$24.38M
Earnings
-$15.16M
Gross Margin
-9.8%
Operating Margin
-53.48%
Profit Margin
-104.5%
Debt to Equity
4.4
Operating Cash Flow
-$14M
Beta
1.49
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
XXII Overview
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XXII's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Tobacco
Industry Rating
C
XXII
Ranked#6 of 8
Ranked#6 of 8
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $58.27 | B | |
| $43.55 | C | |
| $171.36 | C |
Be the first to know about important XXII news, forecast changes, insider trades & much more!
XXII News
Overview
Due Diligence Score
–
Industry Average (34)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XXII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XXII is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XXII is good value based on its book value relative to its share price (0.5x), compared to the US Tobacco industry average (9.45x)
P/B vs Industry Valuation
XXII is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XXII due diligence checks available for Premium users.
Valuation
XXII price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
27.58x
Market
29.18x
XXII price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
9.45x
XXII is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XXII's financial health
Profit margin
Revenue
$4.0M
Net Income
-$4.6M
Profit Margin
-177.8%
XXII's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XXII's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.7M
Liabilities
$17.7M
Debt to equity
4.4
XXII's short-term assets ($11.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XXII's short-term assets ($11.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XXII's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XXII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
-$20.0k
Financing
$3.5M
XXII's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XXII vs Tobacco Stocks
22nd Century Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.